New prostate cancer treatment strategy aims to stop spread before it starts
NCT ID NCT07237269
Summary
This study compares two hormone therapy approaches for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. Researchers want to know if adding the drug abiraterone to standard hormone therapy, along with radiation, works better than standard therapy alone at keeping the cancer from returning. About 140 patients will be randomly assigned to one of the two treatment groups and followed for 5 years to see which approach leads to longer periods without cancer progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.